Nutriband (NASDAQ:NTRB) Trading Down 3.9% – What’s Next?

Nutriband Inc. (NASDAQ:NTRB) shares traded down 3.9% on Tuesday . The stock traded as low as $4.14 and last traded at $4.14. 10,666 shares traded hands during trading, an increase of 6% from the average session volume of 10,048 shares. The stock had previously closed at $4.31.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Nutriband from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce”.

Nutriband Stock Up 1.0%

The stock has a market capitalization of $51.64 million, a price-to-earnings ratio of -1.38 and a beta of 1.78. The company has a quick ratio of 7.35, a current ratio of 7.52 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $4.45 and a 200 day moving average price of $5.59.

Nutriband (NASDAQ:NTRB) last posted its quarterly earnings data on Wednesday, December 10th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.13) by $1.81. Nutriband had a negative return on equity of 133.22% and a negative net margin of 560.89%.The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.68 million. As a group, analysts forecast that Nutriband Inc. will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Cogent Private Wealth Inc. bought a new stake in Nutriband Inc. (NASDAQ:NTRB) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 16,014 shares of the company’s stock, valued at approximately $73,000. Cogent Private Wealth Inc. owned 0.13% of Nutriband at the end of the most recent reporting period. Institutional investors own 19.70% of the company’s stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.